| Dr Jonathan C Lee, MD | |
|
5001 Us Highway 30 W Ste D, Fort Wayne, IN 46818-9701 | |
| (260) 432-1568 | |
| (260) 432-4969 |
| Full Name | Dr Jonathan C Lee |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 12 Years |
| Location | 5001 Us Highway 30 W Ste D, Fort Wayne, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205190147 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lutheran Hospital Of Indiana | Fort wayne, IN | Hospital |
| Marion General Hospital | Marion, IN | Hospital |
| Dupont Hospital Llc | Fort wayne, IN | Hospital |
| Memorial Hospital | Logansport, IN | Hospital |
| Kosciusko Community Hospital | Warsaw, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Radiology Pc | 0143295410 | 75 |
| X-ray Physicians Of Shelbyville Pc | 2264420215 | 44 |
| Kosciusko Medical Group Llc | 5496809956 | 50 |
| Henry County Memorial Hospital | 6002724085 | 112 |
| Decatur County Memorial Hospital | 7315837671 | 66 |
News Archive
New visits for drug-related poisoning in the United States continue to rise; therefore, the American College of Emergency Physicians and the American Association of Poison Control Centers are raising awareness about the dangers of drug poisoning as part of Poison Prevention Week.
Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
› Verified 2 days ago
| Entity Name | Henry County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891570537 PECOS PAC ID: 6002724085 Enrollment ID: O20031121000221 |
News Archive
New visits for drug-related poisoning in the United States continue to rise; therefore, the American College of Emergency Physicians and the American Association of Poison Control Centers are raising awareness about the dangers of drug poisoning as part of Poison Prevention Week.
Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
› Verified 2 days ago
| Entity Name | Decatur County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952300477 PECOS PAC ID: 7315837671 Enrollment ID: O20040318001580 |
News Archive
New visits for drug-related poisoning in the United States continue to rise; therefore, the American College of Emergency Physicians and the American Association of Poison Control Centers are raising awareness about the dangers of drug poisoning as part of Poison Prevention Week.
Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
› Verified 2 days ago
| Entity Name | X-ray Physicians Of Shelbyville Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144351347 PECOS PAC ID: 2264420215 Enrollment ID: O20040506000325 |
News Archive
New visits for drug-related poisoning in the United States continue to rise; therefore, the American College of Emergency Physicians and the American Association of Poison Control Centers are raising awareness about the dangers of drug poisoning as part of Poison Prevention Week.
Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
› Verified 2 days ago
| Entity Name | Summit Radiology Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073584587 PECOS PAC ID: 0143295410 Enrollment ID: O20040831000152 |
News Archive
New visits for drug-related poisoning in the United States continue to rise; therefore, the American College of Emergency Physicians and the American Association of Poison Control Centers are raising awareness about the dangers of drug poisoning as part of Poison Prevention Week.
Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
› Verified 2 days ago
| Entity Name | Kosciusko Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932349594 PECOS PAC ID: 5496809956 Enrollment ID: O20090818000398 |
News Archive
New visits for drug-related poisoning in the United States continue to rise; therefore, the American College of Emergency Physicians and the American Association of Poison Control Centers are raising awareness about the dangers of drug poisoning as part of Poison Prevention Week.
Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan C Lee, MD Po Box 80070, Fort Wayne, IN 46898-0070 Ph: (260) 432-1568 | Dr Jonathan C Lee, MD 5001 Us Highway 30 W Ste D, Fort Wayne, IN 46818-9701 Ph: (260) 432-1568 |
News Archive
New visits for drug-related poisoning in the United States continue to rise; therefore, the American College of Emergency Physicians and the American Association of Poison Control Centers are raising awareness about the dangers of drug poisoning as part of Poison Prevention Week.
Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top line results from the pivotal trial of single agent brentuximab vedotin (SGN-35), an antibody drug conjugate (ADC) targeted to CD30. The trial was conducted in 102 relapsed or refractory Hodgkin lymphoma (HL) patients.
› Verified 2 days ago
Dr. Benjamin Jon Moreno, MD, PHD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3707 New Vision Dr Ste 110, Fort Wayne, IN 46845 Phone: 260-469-6602 Fax: 260-484-5919 | |
Dr. Andre Byard Stovall, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5001 Us Highway 30 W Ste D, Fort Wayne, IN 46818 Phone: 260-432-1568 Fax: 260-432-4969 | |
Dr. Christopher Edson Carrel, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3707 New Vision Dr, Fort Wayne, IN 46845 Phone: 604-696-6022 Fax: 616-363-7290 | |
Dr. Gregg R Mattison, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 3707 New Vision Drive, Fort Wayne, IN 46895 Phone: 260-471-9466 Fax: 260-484-5919 | |
Christopher M Wing, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3707 New Vision Dr, Fort Wayne, IN 46845 Phone: 260-471-9466 Fax: 260-484-5919 | |
Dr. Ahdy Messiha, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 7950 W Jefferson Blvd, Fort Wayne, IN 46804 Phone: 260-432-1568 Fax: 260-432-4969 | |
Vivek K. Sharma, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5001 Us Highway 30 W Ste D, Fort Wayne, IN 46818 Phone: 260-432-1568 Fax: 260-432-4969 |